Communiqués Ultragenyx Pharmaceutical Inc.

Actions

RARE

US90400D1081

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
15,30 ^USD	+3,03%		-40,26%	-33,48%

03/09	Ionis Pharma fixe le prix du premier traitement approuvé par la FDA pour la maladie d'Alexander à 285 000 dollars par dose	RE
03/09	Les plus fortes baisses à la mi-séance	MT

Communiqués

02/09	Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome	GL
01/09	Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease	GL
25/08	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
20/08	Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)	AQ
19/08	Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)	GL
04/08	Ultragenyx: Q2 Earnings Snapshot	AQ
04/08	Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update	GL
28/07	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update	GL
28/07	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update	AQ
24/07	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
08/07	Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact	GL
22/06	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
19/06	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
03/06	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference	GL
01/06	Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm	NE
22/05	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
06/05	Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference	GL
05/05	Ultragenyx: Q1 Earnings Snapshot	AQ
05/05	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update	GL
29/04	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update	GL
27/04	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
24/04	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
08/04	RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026	NE
05/04	RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026	NE
04/04	Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE	BU